An Early Phase 1 interventional study of 68Ga-Pentixafor in Thymoma, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-17.
Sponsored by Peking Union Medical College Hospital · Early Phase 1, Interventional, and Diagnostic
Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.
Thymoma is 1 rare type of tumor developed on the thymic epithelium; patients with thymoma also might have myasthenia gravis (MG). Because of the scarcity and complexity of MG-associated thymoma, its pathogenesis and etiology still remain unclear nowadays. The expression of C-X-C chemokine receptor type 4 (CXCR4) is absent or low in most healthy tissues but highly expressed in various types of tumors. CXCR4 might contribute to the clinical cancer progression, and CXCR4 could be a valuable prognostic biomarker in the therapy of MG-associated thymoma.
133 studies on the registry are indexed under Thymoma; 37 are open to participants now.
This study's planned enrollment of 100 is above the median of 44 across 108 interventional studies indexed under Thymoma.
Browse Thymoma studies →Peking Union Medical College Hospital is the lead sponsor of 1,155 studies on the registry; 475 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Inject 68Ga-Pentixafor and then perform PET/CT scan.
Drug: 68Ga-Pentixafor
Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
Also known as: 68Ga-CXCR4
SUVmax and SUVmean
SUVsof focal lesions are measured on 68Ga-Pentixafor PET/CT. The SUVs of the blood pool and muscle are defined as the background activity on the condition that there is no focally hypermetabolic disease.
Time frame: through study completion, an average of 1.5 years
Diagnostic value
Diagnostic value of 68Ga-Pentixafor PET/CT for thymoma in comparison with 18F-FDG PET/CT or CT or MRI.
Time frame: through study completion, an average of 1.5 years
Diagnostic value in special type of thymoma
Diagnostic value of 68Ga-Pentixafor PET/CT in special type thymoma (A\\AB\\B\\C subtypes)
Time frame: through study completion, an average of 1.5 years
Diagnostic value in thymoma and other masses
Diagnostic value of 68Ga-Pentixafor PET/CT in thymoma and other anterior mediastinal mass.
Time frame: through study completion, an average of 1.5 years
CXCR4 expression and SUV
Correlation between CXCR4 expression and SUV in PET
Time frame: through study completion, an average of 1.5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2024, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 68Ga-pentixafor
Peking Union Medical College Hospital →